Next Article in Journal
Parenting a Child with a Neurodevelopmental Disorder during the Early Stage of the COVID-19 Pandemic: Quantitative and Qualitative Cross-Cultural Findings
Next Article in Special Issue
I Don’t Believe a Person Has to Die When Trying to Get High: Overdose Prevention and Response Strategies in Rural Illinois
Previous Article in Journal
Functional Dentition, Chronic Periodontal Disease and Frailty in Older Adults—A Narrative Review
Previous Article in Special Issue
Barriers and Facilitators of Hepatitis C Care in Persons Coinfected with Human Immunodeficiency Virus
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJERPH
Volume 20
Issue 1
10.3390/ijerph20010501
ijerph-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Pilot Outreach Program in Remedis—The Promising Step toward HCV Elimination among People Who Inject Drugs

by
Laura Krekulová
1,2,*,
Tomáš Damajka
1,
Zuzana Krumphanslová
1 and
Vratislav Řehák
1
1
Remedis, s.r.o., Vladimírova 10, 140 00 Prague 4, Czech Republic
2
4th Department of Internal Medicine, First Faculty of Medicine, Charles University in Prague, Kateřinská 32, 128 00 Prague 2, Czech Republic
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2023, 20(1), 501; https://doi.org/10.3390/ijerph20010501
Submission received: 10 October 2022 / Revised: 20 December 2022 / Accepted: 21 December 2022 / Published: 28 December 2022
(This article belongs to the Special Issue Improving the Health of Individuals Who Inject Drugs)
Browse Figures
Versions Notes

Abstract

:
The global effort to eliminate HCV infection requires new approaches to accessing and testing the affected population in a setting with as low of a threshold as possible. The focus should be on socially marginalized people who inject drugs (PWIDs) and who are not willing or able to visit standard medical services. With this vision, we established an outreach service—a testing point in an ambulance in the park in front of the Main Railway Station of the capital city of Prague—to provide bloodborne disease testing and treatment. The service was available every week on Wednesday afternoon. Over the initial two years of our experience, 168 unique people were tested. Of them, 82 (49%) were diagnosed with chronic HCV infection and were eligible for treatment with antivirals. Of these, 24 (29%) initiated antiviral treatment over the study period, and 17 (71%) of these individuals achieved a documented sustained virological response. Offering medical services in PWIDs’ neighborhoods helps overcome barriers and increase the chances that they will become patients and begin HCV treatment. The described outcomes appear promising for reaching the vision of linkage to the care of such a hard-to-reach population and can serve as a feasible model of care for further expansion.

1. Introduction

Providing care for patients with diagnoses of addiction and other comorbidities is complicated and often requires close collaboration between specialists from different, unrelated fields [1]. A specific risk in people who inject drugs (PWIDs) is the spread of blood-borne infections and the need for their diagnosis and treatment beyond addiction care [2,3]. People who inject psychoactive substances are the main source of new infection outbreaks caused by the hepatitis C virus (HCV) in developed countries [4,5,6].

1.1. WHO Plan to Eliminate HCV Infection Worldwide

Viral hepatitis C is a serious chronic disease that has been classified by the WHO as a general threat [7]. An action plan aimed at the global elimination of HCV infection has been in place since 2016 [8,9]. After the implementation of preventive measures (screening of blood donors, using only disposable injection sets in facilities, etc.), chronic viral hepatitis C began to spread, especially among PWIDs [10,11]. The WHO’s action plan includes targeted care for PWIDs, who were identified by the WHO as one of the most high-risk and at-risk groups [8,9,11]. To eliminate HCV infection and accomplish the WHO’s action plan, testing and treatment must be available for all potential patients, including those from excluded communities and socially marginalized PWIDs [12,13,14,15]. “Test and treat” is the only way to bring the HCV epidemic among PWIDs under control and to eliminate HCV outbreaks among them [11,15].
The need for concurrent treatment of addiction and viral hepatitis creates new, often unpredictable, and difficult-to-resolve obstacles and, therefore, requires close collaboration among health professionals from different disciplines. In theory, we are ready to eliminate HCV infection, but there is an urgent need to change our testing and treatment stra-tegies to reach all at-risk patients and link them to the healthcare system

1.2. Comprehensive Care Program for Patients with Addiction Comorbidity in Remedis, Prague

Two decades before the presentation of the WHO’s international program announcing the global plan for the elimination of hepatitis C (HCV) infection, the Comprehensive Care Program for patients with addiction comorbidity (hereinafter referred to as “CCP”) was created in Remedis in Prague, Czech Republic, to treat patients with liver disease and co-occurring substance use disorders. In accordance with the present WHO recommendations, the CCP has always emphasized the improvement of access to care, diagnostics, and treatment, as well as the inclusion of individuals and groups from excluded communities in medical care and specific HCV treatment. In the year 2019, the Remedis healthcare facility opened a new outreach service, “Ambulance”, to offer medical care to PWIDs more efficiently, with the goal of offering HCV treatment.

1.2.1. The Development and Basic Principles of the Comprehensive Care Program (CCP) in Remedis

Remedis is a single non-state multidisciplinary medical facility. It was founded in Prague in 2000, and in 2014, a branch was established in Brno. The CCP was created as a specific part of this healthcare facility (the evolution of Remedis and the CCP is summarized in Figure 1). The need to address liver diseases in active drug users led to the creation of this interdisciplinary program. The CCP provides patients with a wide range of services in a single healthcare facility. The main objective is to reduce the somatic, psychological, and social risks associated with the use of illicit drugs. Apart from the treatment of infectious diseases, the goal of the comprehensive approach is to establish a long-term collaboration with patients and to help them with lifestyle changes that prevent relapses into substance use, as well as reinfection with viral hepatitis C. Years of experience have shown that sufficient support, empathy, and respect for PWIDs who are living with chronic viral hepatitis C can foster very good collaboration. The facilitated contact improves the doctor–therapist–patient/client–healthcare facility relationships. The goal is to reduce the somatic, psychological, and social risks associated with the use of illicit drugs. Aside from complete abstinence from drugs (which is a major task, but often unattainable), the most important thing is to ensure the stabilization of patients with addiction.
The CCP was developed over time together with the necessity of solving the problems and needs of patients with addiction and chronic viral hepatitis C (see Figure 1). At that time, the only available treatment for chronic viral hepatitis C was interferon treatment [17,18]. This treatment was covered by health insurance, but it required a number of pre-treatment examinations, such as abdominal ultrasound and liver biopsy. In the beginning, we would send our patients who injected drugs to undergo these examinations at different healthcare facilities. The accessibility of healthcare for these patients proved to be very poor. This was the impetus for establishing a healthcare facility that was tailored to the specific needs and options of PWIDs. For the last 10 years, all patients have been provided with comprehensive outpatient care in the fields of internal medicine, hepatology, gastroenterology, gynecology, diabetology, general practice, X-ray, surgery, psychiatry, clinical psychology, social work, and addictology.
The underlying idea of the CCP is a “low-threshold” healthcare facility that provides care for all patients without any further obstacles (requirements for access to healthcare). We do not require PWIDs to have recommendations from a primary care doctor (which they usually do not have), and we make appointments at Remedis flexibly. If possible, we perform all of the necessary examinations in one day, i.e., during one visit to Remedis. Most of the services that we offer are under one roof. Outpatient services are interconnected, and there is no complicated administration, handing over of documentation, or any other standard procedures that often exclude PWID patients from regular healthcare facilities. The basic principles of the CCP are summarized in Table 1.

1.2.2. Care in the Hepatology Center

The cornerstone of the CCP at Remedis is the hepatology clinic, which has been focusing on the diagnosis and treatment of chronic viral hepatitis for many years. An extensive group of patients with chronic viral hepatitis B, C, and D has been diagnosed and treated here. Since 2006, the clinic has had the status of a Center for the Treatment of Viral Hepatitis, as guaranteed by the Czech Society of Hepatology. For several years, it has been the largest hepatology center in the Czech Republic according to the number of patients treated per year. In recent years, in accordance with international and national recommendations for chronic viral hepatitis C treatment, we have been using orally administered direct-acting antivirals (DAAs) that are produced in tablets [19,20,21,22]. We have verified that with the right approach and support for PWIDs, good treatment outcomes can be achieved in this population, which has always been considered as a difficult-to-treat group [7,19,23]. Treatment outcomes (even with the interferon regimens), including the percentage of PWIDs with sustained virological response (SVR), were better in the CCP than treatment outcomes among the general population in registration studies and other projects [24,25]; see Figure 2.

1.2.3. The Latest CCP Service: Off-Site HCV Testing and Treatment in the “Ambulance” Outreach Program

The CCP found that PWIDs accepted the concept of low-threshold specialized healthcare in a clinical setting and further expanded the model to include an outreach component to engage socially vulnerable individuals. In 2018, the CCP at Remedis included new off-site services for PWIDs who were experiencing homelessness. Since June 2019, in collaboration with another nonstate organization, Sananim (namely, with the Sananim terrain programs), a street outreach program offering regular testing for the most common bloodborne and sexually transmitted infections has been in place. The aim of the Remedis outreach initiative is to test as many PWIDs as possible, including socially marginalized individuals who are unlikely to come to a regular healthcare facility or the outpatient CCP in Remedis, Prague. The new medical service is available in an ambulance in the park next to Prague Main Railway Station. For many years, this park has been the center of the illicit drug scene in Prague. Inside the ambulance, Remedis offers professional healthcare services that are run by registered nurses, including blood testing and liver elastography. The outreach service is free of charge, and patients may use it at their own discretion. In an effort to ensure the best possible compliance of and convenience for clients, all of the consultations for results and further recommendations are conducted in the same place, i.e., in the ambulance. If patients are indicated for treatment, they are given an appointment to see a doctor to start this treatment at the CCP Remedis clinic. If necessary, they can be accompanied by a peer or a social worker for this visit. Our objective is to present the results and share our experience with this CCP outreach service, which was evaluated after two years of pilot practice. We describe and present a new model approach to working with PWIDs from socially excluded groups.

2. Methods

2.1. Study Design, Setting, and Participants

This pilot work was monocentric. The study prospectively recruited clients who vo- luntarily used our services in the park next to Prague Main Railway Station and who decided to get tested because of their risky behavior. All self-identified as active injection drug users (a combination of methamphetamine and other illicit drugs, including opiates) and as either having unstable housing or being homeless. Testing was free of charge for all clients. Everyone who contacted the outreach program was tested, and all agreed to be included in the study. There were no obligations associated with participation in this study, which was probably why all clients agreed to participate and provided and signed their informed consent to process their medical history, demographics, and laboratory data. The data from all study participants who contacted the outreach service during the reporting period were included for the purposes of this study.
Standard testing for bloodborne and sexually transmitted diseases from blood samples, which was performed in the outreach setting by a Remedis nurse, was available once per week on Wednesday afternoons. (Ideally, a total volume of 17.5 mL of blood was drawn from a patient through venipuncture. The samples were transported to a certified laboratory in the evening on the same day and immediately processed.) Each test included pre-test counseling, blood sampling and liver elastography. Patient medical history and epidemiological data were obtained from all subjects in the form of an interview and a structured questionnaire, which were used at Remedis in Prague for several years. The first visit also included setting the date of the client’s check-up with the examination results. During this check-up, the results were discussed with the client and other solutions were offered, including specific virostatic therapy in the case of viral hepatitis.

2.2. Laboratory Tests

All subjects were tested for basic serum biochemical parameters (AST, ALT, ALP, GGT, and bilirubin) and contagious diseases: viral hepatitis type A, B, and C, HIV/AIDS, and syphilis. All tests of all collected samples were performed in a certified laboratory using standardized serology tests—commercially available kits—for antibodies. The serology test kits for viral hepatitis A were an Alinity HAVAb IgM, Abbott (Chicago, IL, USA), ALINITY ii analyzer and Alinity HAVAb IgG, Abbott, ALINITY ii analyzer. The initial screening for viral hepatitis B tested for three basic markers: Alinity HBsAg Qualitative II, Abbott, ALINITY ii analyzer, including an HBsAg Confirmatory Test, DiaSorin (Salugia, Italy), LIAISON XL analyzer. The antibodies were Alinity Anti-HBs, Abbott, ALINITY ii analyzer and Alinity Anti-HBc II. An Alinity Anti-HCV, Abbott, ALINITY ii analyzer was used to verify the HCV infection status. For HIV, an Alinity HIV Ag/Ab Combo, Abbott, ALINITY ii analyzer was used; for syphilis, an Alinity Syphilis TP, Abbott, ALINITY ii analyzer and RPR Reagent, Sekure chemistry, Sekisui Medical Co. (Tokyo, Japan), AU 5822 analyzer were used. In the case of positive antigens (HBsAg) or antibodies (anti-HCV), the diagnosis of viral hepatitis B or, rather, viral hepatitis C was further confirmed with virology testing based on direct proof of viral DNA or RNA by using polymerase chain reaction (PCR). Standard diagnostic kits were used to perform diagnostic virology tests. To detect HCV RNA, an Aptima HCV Quant Dx Assay (Hologic, Marlborough, MA, USA), (limit of detection (WHO IS): 7 IU/mL serum, 8 IU/mL plasma) Panther analyzer or HCV Real-TM Quant Dx (Sacace, Como, Italy) was used; for genotyping, HCV Genotype Plus Real-TM (Sacare) was used. When using the Sacace diagnostic kits, the testing was performed on the same RT-PCR cycler Rotor Gene analyzer (Qiagen, Venlo, The Netherlands).

2.3. Epidemiological Data and Statistical Analysis

Personal and demographic data were collected during the assessment of the patients’ history and structured interviews. The data were further processed using the Microsoft Excel 365 statistical program and the IBM SPSS Modeler software. To test the normal distribution of variables, a Shapiro–Wilk test was used. To analyze the significance of differences among particular segments of patients, the Fisher exact test and nonparametric tests were used. Specifically, the Mann–Whitney test, Kruskal–Wallis test, and chi-square test were used. All subjects provided and signed informed consent for inclusion in the study prior to participation.

3. Results

During the two years of the study period, from 26 June 2019 through 30 June 2021, a total of 168 clients were tested within the outreach service in the park next to Prague Main Railway Station. There were 116 males (69%) and 52 females (31%). The average age of all clients was 38.1 years (SD 7.65); the average age of the males was 38.9 years (SD 7.68), and that of the females was 36.3 (SD 7.67). For 81 clients (48%) (54 males and 27 females: 67% and 33%, respectively), this was the very first contact with a Remedis healthcare facility. The remaining 88 clients (52%) (62 males and 26 females: 70% and 30%, respectively) had previous contact with Remedis in some other way. Of those 88, in 23 cases (26%), the first contact with Remedis happened via the Remedis program for prisoners (another Remedis care activity). Only 65 (39%) of the clients had previous experience with the Remedis healthcare facility in Prague.
Of the entire study group, 133 (79%) clients were anti-HCV positive and 32 (21%) were anti-HCV negative, and in three subjects, anti-HCV antibody testing was not performed. These three clients were not serologically tested because of the small amount of serum sample obtained due difficulties in drawing blood. In these cases, we preferred PCR testing. Of the three clients with unknown serological outcomes, two were negative for PCR HCV RNA, and one was positive, with a low viral load and an inability to detect the HCV genotype. However, the patient with low HCV viremia has not contacted the outreach service or any other Remedis programs since then, so a subsequent blood test was not possible. Among the anti-HCV-positive clients, 93 were males (70%) and 40 were females (30%), with the average age of 38.4 years (SD 7.65) (male: 38.8 years (SD 7.66); female: 37.6 years (SD 7.66)). The complete serological results for the entire study group are summarized in Table 2. A detailed analysis did not detect any statistically significant differences between males and females (Table 2). Higher positivity of anti-HAV IgG, anti-HBc, and anti-HCV was detected among patients who were 35 years and older compared to those who were less than 35 years old. None of the clients tested positive for active syphilis.
Almost half of the study sample who had positive anti-HCV antibodies also had detectable HCV RNA in the serum (n = 82, 49%). Sixty-two percent of all individuals with an anti-HCV-positive result had detectable HCV RNA. The other 51 anti-HCV-positive subjects (38%) were negative for HCV RNA, which means that they were without HCV viremia. Among the anti-HCV-positive patients who were positive for PCR HCV RNA, 56 were males (68%) and 26 were females (32%). The average age of the viremic patients was 38.34 years (SD 7.65) (38.5 for males (SD 7.66) and 38.0 for females (SD 7.66)). Genotypes 1 (subtypes 1a and 1b) and 3 were detected among the PCR-positive subjects from the study group. Of all clients tested in the outreach service, 98 (58%) came for the second (check–up) visit and received their results, as well as the post-test counseling and treatment possibilities, if indicated (Figure 3). Of the 82 HCV-PCR-positive clients, 61 (74%) individuals came for the results and the check-up visit and received the information about their HCV infection. All parameters described above and in Table 2 were tested between the groups of clients who did not come for results and those who came and were informed of their results and treatment possibilities. The tests that were carried out did not confirm any statistically significant differences in this case.
Of the 82 patients who were diagnosed with chronic viral hepatitis C and were eligible for specific treatment with DAAs, 24 (29%) PWID patients (13 men and 11 women) were able to start treatment; see Table 3. From this particular subgroup of 82 PCR-HCV-RNA-positive clients, there were 38 subjects (46%) (26 men and 12 women—68% and 32%, respectively) for whom the Remedis outreach service represented their first contact with our healthcare facility regarding bloodborne diseases, and 10 (26%) initiated HCV treatment. The average time between the initial contact with the off-site service and the DAA treatment was more than half a year (6.6 months). The average time between the initial contact with the off-site service and the DAA treatment was significantly longer among females and, furthermore, among clients with an age of 40 and more years.
The majority of those treated for chronic viral hepatitis C were treated in our hepatology center in Remedis (17 subjects, 71%). After being diagnosed in the outreach service, five clients (20%) were treated while imprisoned as a part of the Remedis program for prisoners. Two clients (8%) who were initially diagnosed in the outreach program underwent DAA treatments in a different healthcare institution—IKEM Prague (Institute of Clinical and Experimental Medicine, Prague). The treatment details and the treatment outcomes are unknown to us. However, one of these two men appeared in the outreach service again and was diagnosed as being reinfected with different HCV genotyp. HCV genotype 1 was the most common genotype among the treated patients, and it was detected in 13 individuals (54%), followed by genotype 3 (10 cases, 42%). In one subject (4%), coinfection with genotype 1a/3 was diagnosed. Liver elastography was performed in each client, and the mean fibroscan finding of the treated patients was 9.4 (9.7 in males and 9.0 in females), indicating moderately advanced liver fibrosis—for details, see Table 3 and Figure 4. Sixteen PWID patients were treated with fixed DAA combination of glecaprevir/pibrentasvir, which was the preferred treatment regimen because it took the shortest time for treatment. Two patients were treated with grazoprevir/elbasvir, and four patients with advanced liver fibrosis were treated with sofosbuvir/velpatasvir.
Of 22 clients (11 men and 11 women) treated in Remedis, 17 (77%) reached sustained virological response (SVR—sustained virological response defined as undetectable HCV RNA 12 weeks after treatment completion). SVR was documented more frequently among females (due to the incomplete data of the males, it was not possible to test statistical significance), who needed a longer time to initiate the DAA treatment compared to males (as mentioned above). In this sample, females were more likely to complete the full course of treatment and return for testing/documentation of SVR. Fourteen patients returned for testing for curing 12 weeks after completion of DAA therapy. Three patients had their blood drawn after a longer post-treatment time, and they were also negative for PCR HCV RNA. Four patients who underwent HCV treatment did not come for follow-up testing. One other patient is known to have been reinfected with a different genotype during the post-treatment follow-up (FU) period.

4. Discussion

The WHO has been calling for the global elimination of viral hepatitis C since 2016 [7,8]. The elimination plan is manageable with modern sensitive diagnostic tools and with new direct-acting antivirals that have been available since 2014 [27,28,29]. One of the limits is the price of the treatment [8]. Involving individuals who are at risk for HCV from high-risk subpopulations, such as PWIDs, can be challenging [30,31]. It can be difficult to engage these individuals in care and treatment not only because of their risky behavior (e.g., injecting illicit drugs, practicing sex work, and tattooing), but also because they are socially excluded due to their low income, homelessness, psychiatric disorders, imprisonment, etc. [32,33]. PWIDs may be receiving suboptimal care due to many barriers, including stigma, housing, criminalization, etc. [34]. In addition, another major barrier to HCV testing of PWIDs is venipuncture, which is recognized by both physicians [35] and patients [36].
At present, PWIDs represent a priority population for targeted scale-up of HCV testing and treatment [5,10,37]. Understanding the factors associated with engagement across the HCV cascade of care (CoC) among PWIDs is essential for developing new targeted interventions. Recent research in Australia (where PWIDs’ involvement in the CoC has been very successful) described the CoC among Australian PWIDs and identified factors associated with involvement at each stage. Accordingly, methamphetamine use (as the drug that was most commonly injected in the last month) was associated with a reduced likelihood of antibodies and HCV RNA testing compared with heroin use. A likely reason for this phenomenon would be that heroin users are usually linked in some way to social and health services through opioid agonist treatment (OAT) [38]. Therefore, additional efforts are needed to reach individuals who are not involved in social services, particularly those who do not receive OAT and who predominantly inject methamphetamine [38]. In addition, PWIDs who reported unstable housing were significantly less likely to initiate HCV treatment [38]. This finding is consistent with those of previous research stating that self-reported homelessness is associated with suboptimal HCV treatment uptake [39,40,41,42,43].
High treatment willingness was documented in the homeless population [44], suggesting that improved treatment accessibility could significantly increase HCV care. However, this requires innovative strategies for engaging people experiencing homelessness in HCV treatment [38,41,42,45]. Flexible service and treatment options have demonstrated benefits for highly marginalized populations, including clients who are currently actively injecting drugs and who do not have stable housing [45]. Targeted outreach services are effective methods for delivering HCV care [46,47]. Integrating and linking HCV testing and treatment with other services that PWIDs attend, including those without stable housing, significantly increases access to HCV treatment for these at-risk individuals [48,49,50,51].
Here, we present our new model for engaging marginalized PWIDs with the health system. The established Remedis medical facility has opened a new type of service that tries to help people “out of the system” to engage in testing for HCV and other infectious diseases and, when appropriate, treatment services. We have linked the outreach service directly with the healthcare facility. This new outreach service and its location (in a park near the Main Railway Station in the current center of Prague drug scene) support individuals who are at risk for HCV in establishing the first contact in the outreach setting, then linking with additional services that are available in healthcare facilities. During the first two years, 168 people received HCV testing and counseling. The anti-HCV seroprevalence of 79% was higher than that estimated in the PWID population in the Czech Republic [52,53], which clearly proves that we involved an endangered subgroup of PWIDs. Of 82 patients who were diagnosed with HCV and eligible for HCV treatment, 24 (29%) were treated with DAAs, and of those who completed treatment, 17 (71%) had documented SVR. Patients with SVR were counted according to the ITT analysis. It is very likely that some of the remaining patients who were lost during follow-up (perhaps all of them) also achieved SVR, but we were unable to document this. The number of patients receiving specific treatment for HCV infection in our pilot study is still not ideal, but is higher than in previously presented conventional CoCs [54,55,56,57]—see Figure 4 and Figure 5. We can all take inspiration from several well-functioning national HCV elimination programs (in Georgia, Australia, Scotland, etc.) [58]. Georgia had the highest percentage of DAA treatment uptake in 2019 (50% of current drug users started treatment) [58,59], followed by Australia, where 41% of active drug users started treatment in 2018–2019 [58,60,61].

5. Conclusions

Much work needs to be done to eliminate HCV infection globally. Of the 45 high-income countries, only 11 are on track to meet the WHO’s elimination targets by 2030 [62]. New strategies and targeted interventions are necessary to enhance patient engagement. Here, we try to show that each step taken by medical professionals toward the high-risk PWID subgroup of potential patients is helpful.
Our off-site service allowed 168 people to access testing services. With a low-barrier approach to working with PWIDs and with the respect for their specific needs and barriers, it is possible to establish therapeutic relationships and offer testing and DAA treatment when medically appropriate. The fact that the outreach service operates in an area in which many PWIDs congregate helps them to come and participate. We offer a shortcut for PWIDs to become involved in the professional healthcare system. In addition, the fact that the “Ambulance” outreach program in Remedis has a direct link with the Center for Treatment of Viral Hepatitis of Remedis supports patients’ confidence and decision to participate in HCV treatment regardless of their current social situation. This model is promising and could become one piece of the puzzle of eliminating HCV infection globally.

Author Contributions

L.K. drafted the manuscript and collaborated on the intellectual content. T.D. realized the work with clients in the outreach service in the ambulance car and collected the patients’ data. Z.K. was involved in the revision of the manuscript and prepared the figures, tables, and graphs. V.Ř. is the “father” of the outreach project in Remedis; he was involved in the revision of the manuscript’s intellectual content and provided additional insight and interpretation. All authors have read and agreed to the published version of the manuscript.

Funding

This research received funding from Cooperatio 11158207034-2: gastroenterology.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the institutional ethics committee of Remedis (project identification code: REK0425032019).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study. All subjects gave their written informed consent for inclusion before they participated in the study.

Data Availability Statement

Data sharing not applicable.

Acknowledgments

We would like to thank Victoria Řeháková for the helpful criticism and useful ideas, Hana Krekulová for the help and patience with editing the manuscript, and, last but not least, Cecil H. Hocky for all of his support.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Larney, S.; Peacock, A.; Mathers, B.M.; Hickman, M.; Degenhardt, L. A systematic review of injecting-related injury and disease among people who inject drugs. Drug Alcohol Depend. 2017, 171, 39–49. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Levitt, A.; Mermin, J.; Jones, C.M.; See, A.; Butler, J.C. Infectious Diseases and Injection Drug Use: Public Health Burden and Response. J. Infect. Dis. 2020, 222 (Suppl. 5), S213–S217. [Google Scholar] [CrossRef] [PubMed]
  3. Degenhardt, L.; Charlson, F.; Stanaway, J.; Larney, S.; Alexander, L.T.; Hickman, M.; Cowie, B.; Hall, W.D.; Strang, J.; Whiteford, H.; et al. Estimating the burden of disease attributable to injecting drug use as a risk factorfor HIV, hepatitis C, and hepatitis B: Findings from the Global Burden of Disease Study 2013. Lancet Infect. Dis. 2016, 16, 1385–1398. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. World Health Organization. Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection; World Health Organization: Geneva, Switzerland, 2016. [Google Scholar]
  5. Wiessing, L.; Ferri, M.; Grady, B.; Kantzanou, M.; Sperle, I.; Cullen, K.J.; EMCDDA DRID group; Hatzakis, A.; Prins, M.; Vickerman, P.; et al. Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention. PLoS ONE 2014, 9, e103345. [Google Scholar] [CrossRef]
  6. Grebely, J.; Larney, S.; Peacock, A.; College, S.; Leung, J.; Hickman, M.; Vickerman, P.; Blach, S.; Cunningham, E.B.; Dumchev, K.; et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction 2019, 114, 150–166. [Google Scholar] [CrossRef] [Green Version]
  7. World Health Organization. Global Hepatitis Report 2017; World Health Organization: Geneva, Switzerland, 2017. [Google Scholar]
  8. World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016–2021: Towards Ending Viral Hepatitis; World Health Organization: Geneva, Switzerland, 2016. [Google Scholar]
  9. World Health Organization. Combating Hepatitis B and C to Reach Elimination by 2030: Advocacy Brief; World Health Organization: Geneva, Switzerland, 2016. [Google Scholar]
  10. Degenhardt, L.; Peacock, A.; Colledge, S.; Leung, J.; Grebely, J.; Vickerman, P.; Stone, J.; Cunningham, E.B.; Trickey, A.; Dumchev, K.; et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review. Lancet Glob. Health 2017, 5, e1192–e1207. [Google Scholar] [CrossRef] [Green Version]
  11. Martin, N.K.; Vickerman, P.; Dore, G.J.; Hickman, M. The he-patitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM). Curr. Opin. HIV AIDS 2015, 10, 374–380. [Google Scholar] [CrossRef] [Green Version]
  12. Heffernan, A.; Cooke, G.S.; Nayagam, S.; Thursz, M.; Hallett, T.B. Scaling up prevention and treatment towards the elimination of hepatitis C: A global mathematical model. Lancet 2019, 393, 1319–1329. [Google Scholar] [CrossRef] [Green Version]
  13. Hickman, M.; De Angelis, D.; Vickerman, P.; Hutchinson, S.; Martin, N. Hepatitis C virus treatment as prevention in people who inject drugs. Curr. Opin. Infect. Dis. 2015, 28, 576–582. [Google Scholar] [CrossRef] [Green Version]
  14. Martin, N.K.; Vickerman, P.; Hickman, M. Mathematical modelling of hepatitis C treatment for injecting drug users. J. Theor. Biol. 2011, 274, 58–66. [Google Scholar] [CrossRef]
  15. Harris, M.; Albers, E.; Swan, T. The promise of treatment as pre-vention for hepatitis C: Meeting the needs of people who inject drugs? Int. J. Drug Policy 2015, 26, 963–969. [Google Scholar] [CrossRef] [PubMed]
  16. Krekulova, L. Epidemie Virové Hepatitidy C v Rizikových Populacích: Diagnostika, Léčba a Eliminační Strategie; Stanislav Juhaňák—Triton: Prague, Czech Republic, 2021; ISBN 9788075539311. [Google Scholar]
  17. Poynard, T.; Marcellin, P.; Lee, S.S.; Niederau, C.; Minuk, G.S.; Ideo, G.; Bain, V.; Heathcote, J.; Zeuzem, S.; Trepo, C.; et al. Randomised trial of in-terferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepa-titis C virus. Lancet 1998, 352, 1426–1432. [Google Scholar] [CrossRef] [PubMed]
  18. McHutchison, J.G.; Gordon, S.C.; Schiff, E.R.; Shiffman, M.L.; Lee, W.M.; Rustgi, V.K.; Goodman, Z.D.; Ling, H.M.; Cort, S.; Albrecht, J.K. Interferon Alfa2b Alone or in Combination with Ribavirin as Initial Treatment or Chronic Hepatitis C. N. Engl. J. Med. 1998, 339, 1485–1492. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Ghany, M.G.; Morgan, T.R.; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology 2020, 71, 686–721. [Google Scholar] [CrossRef] [Green Version]
  20. EASL. EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol. 2022, 69, P461–P511. [Google Scholar]
  21. Pawlotsky, J.M.; Negro, F.; Aaghemo, A.; Berenguer, M.; Dalgard, O.; Dusheiko, G.; Marra, F.; Puotti, M.; Wedemeyer, H. EASL recommenda-tions on treatment of hepatitis C: Final update of the series. J. Hepatol. 2020, 73, 1170–1218. [Google Scholar] [CrossRef]
  22. Urbánek, P.; Husa, P.; Šperl, J.; Fraňková, S.; Plíšek, S.; Rožnovský, L.; Kümpel, P. Standard diagnostic and therapeutic approaches to chronic hepatitis C virus infection. Gastroent. Hepatol. 2015, 69, 455–471. [Google Scholar] [CrossRef]
  23. Razavi, H.; Robbins, S.; Zeuzem, V.; Negro, F.; Buti, M.; Duberg, A.S.; Thoraval, F.R.; Craxi, A.; Manns, M.; Marinho, R.T.; et al. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: A modelling study. Lancet Gastroenterol. Hepatol. 2017, 2, 325–336. [Google Scholar] [CrossRef]
  24. Fried, M.W.; Shiffman, M.L.; Reddy, K.R.; Smith, C.; Marinos, G.; Gonçales Jr, F.L.; Häussinger, D.; Diago, M.; Carosi, G.; Dhumeaux, D.; et al. Peginterferon Alfa2a plus Ribavirin for Chronic Hepatitis C Virus Infection. N. Engl. J. Med. 2002, 347, 975–982. [Google Scholar] [CrossRef] [Green Version]
  25. Hadziyannis, S.J.; Sette Jr, H.; Morgan, T.R.; Balan, V.; Diago, M.; Marcellin, P.; Ramadori, G.; Bodenheimer Jr, H.; Bernstein, D.; Rizzetto, M.; et al. Peginter-feron-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C. Ann. Intern. Med. 2004, 140, 975–982. [Google Scholar] [CrossRef]
  26. U.S. Food and Drug Administration. Neurological Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting [Docket No. FDA–2011–N–0002]. In Proceedings of the Antiviral Drugs Advisory Committee Meeting, Silver Spring, MD, USA, 27–28 April 2011. [Google Scholar]
  27. Flisiak, R.; Jaroszewicz, J.; Parfieniuk-Kowerda, A. Emerging treatments for hepatitis C. Expert Opin. Emerg. Drugs 2013, 18, 461–475. [Google Scholar] [CrossRef] [PubMed]
  28. Asselah, T.; Marcellin, P.; Schinazi, R.F. Treatment of hepati-tis C virus infection with direct-acting antiviral agents: 100% cure? Liver Int. 2018, 38, 7–13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. World Health Organization (WHO). Hepatitis C: Key Facts. 2019. Available online: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (accessed on 9 July 2019).
  30. Edland-Gryt, M.; Skatvedt, A.H. Thresholds in a low-thresh-old setting: An empirical study of barriers in a centre for people with drug problems and mental health disorders. Int. J. Drug Policy 2013, 24, 257–264. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  31. Mravcik, V.; Strada, L.; Stolfa, J.; Bencko, V.; Groshkova, T.; Reimer, J.; Schulte, B. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: A literature review. Patient Prefer. Adherence 2013, 7, 1067–1075. [Google Scholar] [CrossRef] [Green Version]
  32. Larney, S.; Peacock, A.; Leung, J.; College, S.; Hickman, M.; Vickerman, P.; Grebely, J.; Dumchev, K.J.; Griffiths, P.; Hinnes, L.; et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C (17)30373-X. Lancet Glob. Health 2017, 5, e1208–e1220. [Google Scholar] [CrossRef] [Green Version]
  33. Hagan, H.; Pouget, E.R.; Des Jarlais, D.C. A Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs. J. Infect. Dis. 2011, 204, 74–83. [Google Scholar] [CrossRef]
  34. Harris, M.; Rhodes, T. Hepatitis C treatment access and uptake for people who inject drugs: A review mapping the role of social factors. Harm Reduct. J. 2013, 10, 7. [Google Scholar] [CrossRef] [Green Version]
  35. Marshall, A.D.; Grebely, J.; Dore, G.J.; Treloar, C. Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists—The practitioner experience. Drug Alcohol Depend. 2020, 206, 107705. [Google Scholar] [CrossRef]
  36. Madden, A.; Hopwood, M.; Neale, J.; Treloar, C. Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs? PLoS ONE 2018, 13, e0207226. [Google Scholar] [CrossRef]
  37. Larney, S.; Grebely, J.; Hickman, M.; Angelis, D.D.; Dore, G.J.; Degenhardt, L. Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs. Int. J. Drug Policy 2015, 26, 950–957. [Google Scholar] [CrossRef]
  38. Gibbs, D.; Price, O.; Grebely, J.; Larney, S.; Sutherland, R.; Read, P.; Butler, K.; Degenhardt, L.; Peacock, A. Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system. Drug Alcohol Depend. 2021, 228, 109050. [Google Scholar] [CrossRef] [PubMed]
  39. Bajis, S.; Grebely, J.; Hajarizadeh, B.; Applegate, T.; Marshall, A.D.; Harrod, M.E.; Byrne, J.; Bath, N.; Read, P.; Edwards, M.; et al. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre-and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study. J. Viral Hepat. 2020, 27, 281–293. [Google Scholar] [CrossRef] [PubMed]
  40. Butler, K.; Larney, S.; Day, C.A.; Burns, L. Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system. Drug Alcohol Rev. 2019, 38, 264–269. [Google Scholar] [CrossRef] [PubMed]
  41. Harney, B.L.; Whitton, B.; Lim, C.; Paige, E.; Mcdonald, B.; Nolan, S.; Pemberton, D.; Hellard, M.E.; Doyle, J.S. Quantitative evaluation of an integrated nurse model of care providing hepatitis C treatment to people attending homeless services in Melbourne, Australia. Int. J. Drug Policy 2019, 72, 195–198. [Google Scholar] [CrossRef]
  42. Beiser, M.E.; Smith, K.; Ingemi, M.; Mulligan, E.; Baggett, T.P. Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston. Int. J. Drug Policy 2019, 72, 129–137. [Google Scholar] [CrossRef]
  43. Valerio, H.; Alavi, M.; Conway, A.; Silk, D.; Treloar, C.; Martinello, M.; Milat, A.; Dunlop, A.; Murray, C.; Henderson, C.; et al. Declining Prevalence of Current HCV Infection and Increased Treatment Uptake Among People Who Inject Drugs: The ETHOS Engage Study. Int. J. Drug Policy 2022, 105, 103706. [Google Scholar] [CrossRef]
  44. Beiser, M.; Leon, C.; Gaeta, J.M. Needs assessment of HCV-infected individuals experiencing homelessness and implications. J. Health Care Poor Underserved 2017, 28, 596–606. [Google Scholar] [CrossRef]
  45. Read, P.; Lothian, R.; Chronister, K.; Gilliver, R.; Kearley, J.; Dore, G.J.; van Beek, I. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int. J. Drug Policy 2017, 47, 209–215. [Google Scholar] [CrossRef]
  46. Broad, J.; Mason, K.; Guyton, M.; Lettner, B.; Matelski, J.; Powis, J. Peer outreach point-of-care testing as a bridge to hepatitis C care for people who inject drugs in Toronto, Canada. Int. J. Drug Policy 2020, 80, 102755. [Google Scholar] [CrossRef]
  47. Surey, J.; Menezes, D.; Francis, M.; Gibbons, J.; Sultan, B.; Miah, A.; Abubakar, I.; Story, A. From peer-based to peer-led: Redefining the role of peers across the hepatitis C care pathway: HepCare Europe. J. Antimicrob. Chemother. 2019, 74 (Suppl. 5), v17–v23. [Google Scholar] [CrossRef]
  48. Socias, M.; Karamouzian, M.; Parent, S.; Barletta, J.; Bird, K.; Ti, L. Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review. Int. J. Drug Policy 2019, 72, 146–159. [Google Scholar] [CrossRef] [PubMed]
  49. Treloar, C.; Rance, J.; Dore, G.J.; Grebely, J. Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: Insights from the ETHOS study. J. Viral Hepat. 2014, 21, 560–567. [Google Scholar] [CrossRef] [PubMed]
  50. Oru, E.; Trickey, A.; Shirali, R.; Kanters, S.; Easterbrook, P. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: A global systematic review and meta-analysis. Lancet Glob. Health 2021, 9, e431–e445. [Google Scholar] [CrossRef] [PubMed]
  51. Stvilia, K.; Vephkvadze, N.; Gamkrelidze, A.; Khonelidze, I.; Getia, V.; Tsereteli, M.; Gvinjilia, L.; Kuchuloria, T. Hepatitis C treatment uptake among patients who have received methadone substitution treatment in the Republic of Georgia. Public Health 2021, 195, 42–50. [Google Scholar] [CrossRef]
  52. Zabransky, T.; Mravcik, V.; Korcisova, B.; Rehak, V. Hepatitis C Virus Infection among Injecting Drug Users in the Czech Republic—Prevalence and Associated Factors. Eur. Addict. Res. 2006, 12, 151–160. [Google Scholar] [CrossRef]
  53. Mravcik, V.; Chomynova, P.; Grohmanova, K.; Janikova, B.; Černíková, T.; Rous, Z.; Leštinová, T.; Nechanská, B.; Cibulka, J.; Fidesova, H.; et al. Výroční Zpráva o Stavu ve Věcech Drog v České Republice v Roce 2018 (Annual Report on Drug Situation 2018—Czech Republic); Úřad Vlády ČR: Prague, Czech Republic, 2019; ISBN 9788074402371. [Google Scholar]
  54. Razavi, H.; Waked, I.; Sarrazin, C.; Myers, R.P.; Idilman, R.; Calinas, F.; Vogel, W.; Mendes Correa, M.C.; Hézode, C.; Lázaro, P.; et al. The present and future di-sease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J. Viral Hepat. 2014, 21 (Suppl. 1), 34–59. [Google Scholar] [CrossRef]
  55. Grebely, J.; Raffa, J.D.; Lai, C.; Krajden, M.; Kerr, T.; Fischer, B.; Tyndall, M.W. Low uptake of treatment for hepatitis C virus infec-tion in a large community-based study of inner city residents. J. Viral Hepat. 2009, 16, 352–358. [Google Scholar] [CrossRef] [Green Version]
  56. Mehta, S.H.; Genberg, B.L.; Astemborski, J.; Kavasery, R.; Kirk, G.D.; Vlahov, D.; Strathdee, S.A.; Thomas, D.L. Limited Uptake of Hepatitis C Treatment Among Injection Drug Users. J. Commun. Health 2008, 33, 126–133. [Google Scholar] [CrossRef]
  57. Grebely, J.; Bruggmann, P.; Treloar, C.; Byrne, J.; Rhodes, T.; Dore, G.J. Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs. Int. J. Drug Policy 2015, 26, 893–898. [Google Scholar] [CrossRef]
  58. Yousafzai, M.T.; Bajis, S.; Alavi, M.; Grebely, J.; Dore, G.J.; Hajarizadeh, B. Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis. J. Viral Hepat. 2021, 28, 1340–1354. [Google Scholar] [CrossRef]
  59. Stvilia, K.; Khonelidze, I.; Gamkrelidze, A.; Asatiaan, A.; Ruadze, E.; Gogia, M.; Kutateladze, K.; Jikhia, G. HCV care cascade of PWIDs reached within the Global Fund Needle and Syringe Program (NSP) in Georgia. J. Hepatol. 2019, 70, e343. [Google Scholar] [CrossRef]
  60. Iversen, J.; Dore, G.J.; Catlett, B.; Cunningham, P.; Grebely, J.; Maher, L. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. J. Hepatol. 2019, 70, 33–39. [Google Scholar] [CrossRef] [PubMed]
  61. Iversen, J.; Dore, G.J.; Starr, M.; Catlett, B.; Cunningham, P.; Geddes, L.; Maher, L. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy. Int. J. Drug Policy 2020, 83, 102837. [Google Scholar] [CrossRef] [PubMed]
  62. Gamkrelidze, I.; Pawlotsky, J.M.; Lazarus, J.V.; Feld, J.J.; Zeuzem, S.; Bao, Y.; Pires dos Santos, A.G.; Gonzalez, Y.S.; Razavi, H. Progress towards hepatitis C virus elimination in high-income countries: An updated analysis. Liver Int. 2021, 41, 456–463. [Google Scholar] [CrossRef] [PubMed]
Ijerph 20 00501 g001 550
Figure 1. Development of the Comprehensive Care Program for patients with addiction comorbi- dity in the Remedis healthcare facility in Prague and Brno in the Czech Republic [16].
Figure 1. Development of the Comprehensive Care Program for patients with addiction comorbi- dity in the Remedis healthcare facility in Prague and Brno in the Czech Republic [16].
Ijerph 20 00501 g001
Ijerph 20 00501 g002 550
Figure 2. Remedis treatment outcomes for HCV-infected PWID patients treated with pegylated interferons and ribavirin in the years 2005–2010 (SVR 81.4% orange circle) compared with those in registration studies with pegylated interferons and ribavirin realized in the general population—orange circle on bar graph SVR 56% (left side (pie chart)—data from Remedis, Prague; right side (bar graph)—evolution of chronic viral hepatitis C treatment modalities and increase in the efficacy of viral clearance measured as sustained virological response). SVR—sustained virological response: defined as undetectable HCV RNA 24 weeks after treatment completion, IFN—interferon, RBV—ribavirin, PEG-IFN—pegylated interferon, DAA—direct-acting antivirals (adapted from the US Food and Drug Administration’s Antiviral Drugs Advisory Committee Meeting, 27–28 April 2011, Silver Spring, MD, USA) [16,24,25,26].
Figure 2. Remedis treatment outcomes for HCV-infected PWID patients treated with pegylated interferons and ribavirin in the years 2005–2010 (SVR 81.4% orange circle) compared with those in registration studies with pegylated interferons and ribavirin realized in the general population—orange circle on bar graph SVR 56% (left side (pie chart)—data from Remedis, Prague; right side (bar graph)—evolution of chronic viral hepatitis C treatment modalities and increase in the efficacy of viral clearance measured as sustained virological response). SVR—sustained virological response: defined as undetectable HCV RNA 24 weeks after treatment completion, IFN—interferon, RBV—ribavirin, PEG-IFN—pegylated interferon, DAA—direct-acting antivirals (adapted from the US Food and Drug Administration’s Antiviral Drugs Advisory Committee Meeting, 27–28 April 2011, Silver Spring, MD, USA) [16,24,25,26].
Ijerph 20 00501 g002
Ijerph 20 00501 g003 550
Figure 3. All tested clients in proportion to those who received their test results and were aware of their HCV infection.
Figure 3. All tested clients in proportion to those who received their test results and were aware of their HCV infection.
Ijerph 20 00501 g003
Ijerph 20 00501 g004 550
Figure 4. Cascade of care of the Remedis “Ambulance” outreach program. N/A—data not available (genotypes tested with uncertain results); DAA—direct-acting antivirals; SVR—sustained virological response defined as undetectable HCV RNA 12 weeks after treatment completion.
Figure 4. Cascade of care of the Remedis “Ambulance” outreach program. N/A—data not available (genotypes tested with uncertain results); DAA—direct-acting antivirals; SVR—sustained virological response defined as undetectable HCV RNA 12 weeks after treatment completion.
Ijerph 20 00501 g004
Ijerph 20 00501 g005 550
Figure 5. WHO cascade of care. HCP—healthcare professional, SVR—sustained virological response (adapted from: World Health Organization. Global hepatitis report, 2017. Geneva: World Health Organization [7]).
Figure 5. WHO cascade of care. HCP—healthcare professional, SVR—sustained virological response (adapted from: World Health Organization. Global hepatitis report, 2017. Geneva: World Health Organization [7]).
Ijerph 20 00501 g005
Table
Table 1. Basic principles of the Comprehensive Care Program (CCP) for patients with addiction comorbidity [16].
Table 1. Basic principles of the Comprehensive Care Program (CCP) for patients with addiction comorbidity [16].
Basic Principles
Comprehensive Care Program for Patients with Addiction Comorbidity
▪
Access to health care and preventive care with no restrictions
▪
Everything is under one roof—easy access to health care
▪
Easy-to-use system for making appointments
▪
Working hours adjusted to the patients’ needs—time available health care
▪
Interconnected services—follow-up care
▪
Individual diagnostic and treatment plan for each patient
▪
Friendly, proactive approach to patients at all levels of contact and care
▪
Dissemination of information by patients themselves (peer to peer)
▪
Using feedback from patients to evaluate and further improve CCP’s services and make them even more available.
Table
Table 2. Serological results. N/A—not available (patients were not serologically tested due to a small amount of serum sample).
Table 2. Serological results. N/A—not available (patients were not serologically tested due to a small amount of serum sample).
ClientsResultsAnti
HAV-IgM		Anti
HAV-IgG		HBsAgAnti-HBcAnti-HBsAnti-HCVAnti-HIV
n = 168positive096069891330
negative16166164947632168
N/A7645330
Total 168168168168168168168
Femalepositive03001733400
negative51215033181052
N/A1122120
Total 52525252525252
Malepositive06605256930
negative11045114615822116
N/A6523210
Total 116116116116116116116
Table
Table 3. PWID clients recruited in the outreach program who successfully started DAA treatment. PIB—pibrentasvir, GLE—glecaprevir, GZR—grazoprevir, EBR—elbasvir, SOF—sofosbuvir, VEL—vepatasvir, SVR—sustained virological response defined as undetectable HCV RNA 12 weeks after treatment completion, N/A—data not available, Ø—average; Office—doctor’s office in the Remedis outpatient clinic; O—other healthcare facility; * treatment realized in another healthcare facility (IKEM Prague); ** HCV reinfection confirmed by PCR.
Table 3. PWID clients recruited in the outreach program who successfully started DAA treatment. PIB—pibrentasvir, GLE—glecaprevir, GZR—grazoprevir, EBR—elbasvir, SOF—sofosbuvir, VEL—vepatasvir, SVR—sustained virological response defined as undetectable HCV RNA 12 weeks after treatment completion, N/A—data not available, Ø—average; Office—doctor’s office in the Remedis outpatient clinic; O—other healthcare facility; * treatment realized in another healthcare facility (IKEM Prague); ** HCV reinfection confirmed by PCR.
Patient’s
Number		Gender
Male/Female		Age1st Contact
with Remedis		1st Contact
in Ambulance
(MM/YYYY)		HCV GenotypeFIBROSCAN
(kPa)		HCV
Treatment
Started (MM/YYYY)		Time from
1st Contact till
Treatment (M)		Where TreatedTreatment
Regimen		SVR Yes/No
1F36Ambulance12/20191a5.87/20207PRISONPIB/GLEYES
2F33OFFICE10/20191a4.32/20204OFFICEPIB/GLEYES
3F51Ambulance2/20201b9.910/20208OFFICEGZR/EBRYES
4M45Ambulance10/2019310.19/202011OFFICEPIB/GLEN/A
5M59OFFICE7/20191a12.83/202120PRISONPIB/GLEN/A
6F37OFFICE8/202038.53/20217OFFICEPIB/GLEYES
7M36Ambulance1/202037.12/20201OFFICEPIB/GLENO **
8M38PRISON1/20201a7.81/20200OFFICEPIB/GLEN/A
9M50OFFICE11/2019301/20200O *N/AN/A **
10F26Ambulance2/202036.25/20203OFFICESOF/VELYES
11M34Ambulance1/20201a06/20200O *N/AN/A
12F39OFFICE7/201937.310/20193OFFICEPIB/GLEYES
13M37OFFICE2/20201a11.34/202114OFFICEPIB/GLEYES
14M38OFFICE9/2019343.710/20191OFFICESOF/VELYES
15F40Ambulance10/20191a/1b76/202120PRISONPIB/GLEYES
16F28Ambulance1/20203/1a4.74/20203OFFICEPIB/GLEYES
17M35Ambulance3/202138.84/20211OFFICESOF/VELN/A
18F41OFFICE11/2019387/20208PRISONPIB/GLEYES
19F40OFFICE7/20191a33.510/202015OFFICESOF/VELYES
20M37OFFICE11/20191a6.42/20203OFFICEPIB/GLEYES
21M43Ambulance10/20191a6.111/20191OFFICEPIB/GLEYES
22F37OFFICE7/20191b45/202010PRISONGZR/EBRYES
23M43OFFICE10/201936.62/20204OFFICEPIB/GLEYES
24M38OFFICE10/20201b5.112/20202OFFICEPIB/GLEYES
Ø 39.2 Ø 9.4 Ø 6.08
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Krekulová, L.; Damajka, T.; Krumphanslová, Z.; Řehák, V. Pilot Outreach Program in Remedis—The Promising Step toward HCV Elimination among People Who Inject Drugs. Int. J. Environ. Res. Public Health 2023, 20, 501. https://doi.org/10.3390/ijerph20010501

AMA Style

Krekulová L, Damajka T, Krumphanslová Z, Řehák V. Pilot Outreach Program in Remedis—The Promising Step toward HCV Elimination among People Who Inject Drugs. International Journal of Environmental Research and Public Health. 2023; 20(1):501. https://doi.org/10.3390/ijerph20010501

Chicago/Turabian Style

Krekulová, Laura, Tomáš Damajka, Zuzana Krumphanslová, and Vratislav Řehák. 2023. "Pilot Outreach Program in Remedis—The Promising Step toward HCV Elimination among People Who Inject Drugs" International Journal of Environmental Research and Public Health 20, no. 1: 501. https://doi.org/10.3390/ijerph20010501

APA Style

Krekulová, L., Damajka, T., Krumphanslová, Z., & Řehák, V. (2023). Pilot Outreach Program in Remedis—The Promising Step toward HCV Elimination among People Who Inject Drugs. International Journal of Environmental Research and Public Health, 20(1), 501. https://doi.org/10.3390/ijerph20010501

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop